{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:42:58Z","timestamp":1762548178591,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"2024 Basic and Applied Basic Research Topic of Guangzhou Science and Technology Project","award":["2024A04J4710"],"award-info":[{"award-number":["2024A04J4710"]}]},{"name":"the Shenzhen Postdoctoral Research Fund"},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515110893","2023A1515220088"],"award-info":[{"award-number":["2022A1515110893","2023A1515220088"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003785","name":"Guangdong Provincial Medical Research Foundation","doi-asserted-by":"publisher","award":["A2023384"],"award-info":[{"award-number":["A2023384"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32301121"],"award-info":[{"award-number":["32301121"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017607","name":"Shenzhen Basic Research Program","doi-asserted-by":"publisher","award":["JCYJ20220530145200001"],"award-info":[{"award-number":["JCYJ20220530145200001"]}],"id":[{"id":"10.13039\/501100017607","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Medical Scientific Research Foundation of Guangzhou City","award":["20241A011091"],"award-info":[{"award-number":["20241A011091"]}]},{"DOI":"10.13039\/501100021171","name":"Guangdong\u00a0Basic\u00a0and Applied Basic Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clim.2025.110534","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T11:58:50Z","timestamp":1748433530000},"page":"110534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["PD\u20101 monoclonal antibody (Tislelizumab)-induced DRESS syndrome in an intrahepatic cholangiocarcinoma patient with FGFR3 mutation and elevated IgG4:A case report"],"prefix":"10.1016","volume":"278","author":[{"given":"Wei","family":"Qin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiongyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangling","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenya","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingyu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songlin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clim.2025.110534_bb0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.clim.2025.110534_bb0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.clim.2025.110534_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002879","article-title":"Nivolumab-associated DRESS in a genetic susceptible individual","volume":"9","author":"Ai","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.clim.2025.110534_bb0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000000877","article-title":"Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases","volume":"33","author":"Ingen-Housz-Oro","year":"2023","journal-title":"Melanoma Res."},{"issue":"6","key":"10.1016\/j.clim.2025.110534_bb0025","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/jso.24569","article-title":"Comparative performances of the 7th and the 8th editions of the American joint committee on Cancer staging systems for intrahepatic cholangiocarcinoma","volume":"115","author":"Spolverato","year":"2017","journal-title":"J. Surg. Oncol."},{"issue":"10","key":"10.1016\/j.clim.2025.110534_bb0030","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.22.01142","article-title":"Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: A multicenter, phase III, randomized study","volume":"41","author":"Li","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.clim.2025.110534_bb0035","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41392-023-01604-3","article-title":"Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.clim.2025.110534_bb0040","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2133.2006.07284.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"155","author":"Peyri\u00e8re","year":"2006","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.clim.2025.110534_bb0045","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/CMR.0000000000000326","article-title":"Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome","volume":"27","author":"Mirza","year":"2017","journal-title":"Melanoma Res."},{"issue":"1","key":"10.1016\/j.clim.2025.110534_bb0050","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","article-title":"Targeting FGFR for cancer therapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.clim.2025.110534_bb0055","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"ESMO guidelines committee. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.clim.2025.110534_bb0060","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaip.2022.02.004","article-title":"Drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis","volume":"10","author":"Hama","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.clim.2025.110534_bb0065","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"issue":"10391","key":"10.1016\/j.clim.2025.110534_bb0070","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with 6 advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"60","key":"10.1016\/j.clim.2025.110534_bb0075","doi-asserted-by":"crossref","first-page":"eaba8426","DOI":"10.1126\/sciimmunol.aba8426","article-title":"All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages","volume":"6","author":"Rao","year":"2021","journal-title":"Sci Immunol."},{"issue":"1","key":"10.1016\/j.clim.2025.110534_bb0080","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41392-023-01604-3","article-title":"Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.clim.2025.110534_bb0085","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1158\/1078-0432.CCR-22-2495","article-title":"Targeting MDSC differentiation using ATRA: a phase I\/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma","volume":"29","author":"Tobin","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2025.110534_bb0090","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cca.2018.06.032","article-title":"Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells","volume":"485","author":"Qiu","year":"2018","journal-title":"Clin. Chim. Acta"},{"issue":"2","key":"10.1016\/j.clim.2025.110534_bb0095","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2169\/internalmedicine.1480-22","article-title":"Nivolumab therapy in lung cancer associated with IgG4-related disease","volume":"63","author":"Aso","year":"2024","journal-title":"Intern. Med."},{"issue":"11","key":"10.1016\/j.clim.2025.110534_bb0100","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood.2019003886","article-title":"Nivolumab treatment for relapsed\/refractory Epstein-Barr virus-associated hemophagocytic lymphohistocytosis in adults","volume":"135","author":"Liu","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clim.2025.110534_bb0105","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/rheumatology\/keab360","article-title":"The role of PD-1\/PD-ls in the pathogenesis of IgG4-related disease","volume":"61","author":"Zhang","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.clim.2025.110534_bb0110","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41416-018-0261-0","article-title":"Everolimus and pazopanib (E\/P) benefit genomically selected patients with metastatic urothelial carcinoma","volume":"119","author":"Bellmunt","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"21","key":"10.1016\/j.clim.2025.110534_bb0115","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"THOR cohort 1 investigators. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.clim.2025.110534_bb0120","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaci.2020.08.003","article-title":"Taiwan\/Asian severe cutaneous adverse reaction consortium. Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians","volume":"147","author":"Wang","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2025.110534_bb0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2169\/internalmedicine.1847-23","article-title":"HLA-DRB1 is associated with therapeutic responsiveness in IgG4-related disease","volume":"63","author":"Yamamoto","year":"2024","journal-title":"Intern. Med."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625001093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625001093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:37:57Z","timestamp":1762547877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661625001093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":25,"alternative-id":["S1521661625001093"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2025.110534","relation":{},"ISSN":["1521-6616"],"issn-type":[{"type":"print","value":"1521-6616"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD\u20101 monoclonal antibody (Tislelizumab)-induced DRESS syndrome in an intrahepatic cholangiocarcinoma patient with FGFR3 mutation and elevated IgG4:A case report","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2025.110534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110534"}}